Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages after chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide

被引:51
|
作者
Kasapovic, Jelena [1 ]
Pejic, Snezana [1 ]
Stojiljkovic, Vesna [1 ]
Todorovic, Ana [1 ]
Radosevic-Jelic, Ljiljana [2 ]
Saicic, Zorica S. [3 ]
Pajovic, Snezana B. [1 ]
机构
[1] Univ Belgrade, Vinca Inst Nucl Sci, Lab Mol Biol & Endocrinol, Belgrade 11000, Serbia
[2] Univ Belgrade, Inst Oncol & Radiol Serbia, Belgrade, Serbia
[3] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Physiol, Belgrade, Serbia
关键词
Lipid peroxidation; Antioxidants; Breast cancer; Chemotherapy; Radiotherapy; Aging; OXIDATIVE STRESS; PLASMA; RADIOTHERAPY; ADRIAMYCIN; APOPTOSIS; SYSTEM;
D O I
10.1016/j.clinbiochem.2010.08.009
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Breast carcinoma is related to the increase of lipid peroxidation in plasma with concomitant decrease of antioxidant (AO) defense capacity in blood cells, which becomes more pronounced during aging of the patients. This work evaluated the potential age-related effect of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) on the level of lipid hydroperoxides (LP), glutathione (GSH), AO enzyme activities of copper, zinc superoxide dismutase (CuZnSOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase (GR) in breast cancer patients. The level of CuZnSOD protein was assessed after the FAC therapy and radiotherapy of breast cancer. Design and methods: AO parameters were measured in the blood of 58 breast cancer patients and 60 healthy age-matched healthy subjects by biochemical and Western blot analyses. Results: Increased oxidative stress (LP: p<0.05) and decreased AO enzyme activities (CuZnSOD: p<0.01, GPx: p<0.05, GR: p<0.01) and GSH level (p<0.01) in the blood of breast cancer patients in response to FAC chemotherapy seem not to be age-dependent. CuZnSOD enzyme expression decreased after the FAC chemotherapy (p<0.05), while it increased after the radiotherapy of breast cancer (p<0.05). Conclusion: FAC chemotherapy and radiotherapy promote further oxidative shift, which potentiate already existing chronic oxidative stress linked to breast cancer. In these effects, impaired capacity for H2O2 detoxification (CAT. GPX and GSH) seems to have major contribution. (C) 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1287 / 1293
页数:7
相关论文
共 50 条
  • [1] Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages
    Kasapovic, Jelena
    Pejic, Snezana
    Todorovic, Ana
    Stojiljkovic, Vesna
    Pajovic, Snezana B.
    [J]. CELL BIOCHEMISTRY AND FUNCTION, 2008, 26 (06) : 723 - 730
  • [2] Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
    Tecza, Karolina
    Pamula-Pilat, Jolanta
    Lanuszewska, Joanna
    Grzybowska, Ewa
    [J]. ONCOTARGET, 2016, 7 (41) : 66790 - 66808
  • [3] Doxorubicin and Cyclophosphamide versus Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Adjuvant Chemotherapy in Breast Cancer
    Livi, L.
    Saieva, C.
    Borghesi, S.
    Cardillo, C. De Luca
    Scotti, V.
    Mangoni, M.
    Greto, D.
    Cataliotti, L.
    Paiar, F.
    Bianchi, S.
    Biti, G. P.
    [J]. JOURNAL OF CHEMOTHERAPY, 2009, 21 (05) : 558 - 565
  • [4] COMBINATION CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, MITOXANTRONE AND 5-FLUOROURACIL IN PATIENTS WITH METASTATIC BREAST-CANCER
    YAP, HY
    ESPARZA, L
    BLUMENSCHEIN, GR
    HORTOBAGYI, GN
    BODEY, GP
    [J]. CANCER TREATMENT REVIEWS, 1983, 10 : 53 - 55
  • [5] RESULTS OF INITIAL DOXORUBICIN, 5-FLUOROURACIL, AND CYCLOPHOSPHAMIDE COMBINATION CHEMOTHERAPY FOR INFLAMMATORY CARCINOMA OF THE BREAST
    MALOISEL, F
    DUFOUR, P
    BERGERAT, JP
    HERBRECHT, R
    DUCLOS, B
    BOILLETOT, A
    GIRON, C
    JAECK, D
    HAENNEL, P
    JUNG, G
    OBERLING, F
    [J]. CANCER, 1990, 65 (04) : 851 - 855
  • [6] Lipid peroxidation and antioxidant status in patients with breast cancer
    Rajneesh, C. P.
    Manimaran, A.
    Sasikala, K. R.
    Adaikappan, P.
    [J]. SINGAPORE MEDICAL JOURNAL, 2008, 49 (08) : 640 - 643
  • [7] A pilot study of continuous infusional 5-fluorouracil, doxorubicin and cyclophosphamide in breast cancer
    Mackay, HJ
    Bissett, D
    Twelves, C
    Vasey, PA
    [J]. CLINICAL ONCOLOGY, 1999, 11 (03) : 174 - 178
  • [8] NEOADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, DOXORUBICIN AND 5-FLUOROURACIL (CAF) OR CYCLOPHOSPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL (CMF) IN 69 CASES OF LOCALLY ADVANCED (STAGE-IIIB) BREAST-CANCER
    GUPTA, P
    BIJLANI, L
    RATH, GK
    MISRA, A
    MISHRA, MC
    SHUKLA, NK
    KRIPLANI, A
    KAPUR, BML
    [J]. JAPANESE JOURNAL OF SURGERY, 1991, 21 (06): : 637 - 642
  • [9] HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer
    Pusztai, L.
    Andre, F.
    Mazouni, C.
    Liedtke, C.
    Kau, S.
    Frye, D.
    Green, M.
    Gonzalez-Angulo, A. M.
    Symmans, W. F.
    Hortobagyi, G. N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Pharmacogenomic predictor of complete response to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer.
    Pusztai, L.
    Hess, K. R.
    Anderson, K.
    Valero, V.
    Ibrahim, N. K.
    Mejia, J. A.
    Vidaurre, T.
    Gomez, H. L.
    Hortobagyi, G. N.
    Symmans, W. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 541S - 541S